Ann: Completion of Entitlement Offer, page-8

Steini, your constant alarmist remarks are bordering on absurd. Get your facts straight before posting or kindly STFU.

CHMs CDH17 CART therapy is potentially a game changer in the oncology space. First ever 3 rd generation CART, developed by the pioneers of CART at UPenn, that targets CDH17, that is showing early signs of efficacy at the lowest dosage against colorectal AND pancreatic cancers.

I can point to comparable companies with multi billion dollar valuations that are in registrational phase 3 trials that have shifted PFS and OS by a few months to the right for pancreatic cancer alone. CHM can potentially be in a registrational trial in a few months for CDH17.